You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mutation Enriched Targeted Re Sequencing
SBC: TRANSGENOMIC, INC. Topic: 103DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis
SBC: Sanguine Diagnostics And Therapeutics, Inc. Topic: 103ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer
SBC: ACTORIUS PHARMACEUTICALS, LLC Topic: 100DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
IMPROVING THE TREATMENT OF CONTAMINATED AQUIFERS BYDEVELOPING DIRECT-PUSH OXIDANT CANDLES WITH PNEUMATIC CIRCULATORS
SBC: AirLIft Environmental LLC Topic: NIEHSDESCRIPTION provided by applicant Clean water is one of the most basic societal needs in the world Few situations incite more public outcry than when a community learns that their drinking water has been tainted Two of the biggest threats to groundwater quality in the U S are contamination from either chlorinated solvents or petroleum Left unattended the size and scope of the problems asso ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: NIAMSDESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Bioassay Methods for Standardization of Immune Enhancing Dietary Supplements
SBC: PSI (Phytochemical Services, Incorporated) Topic: 213DESCRIPTION provided by applicant Clinical trials testing the potential health benefits of immune enhancing dietary supplements have produced inconsistent results A major problem contributing to these inconsistent outcomes is that these studies have used a wide variety of poorly characterized products Attempts to solve this product quality control problem using chemical standardization method ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Transmucosal Intra-Oral Drug Delivery System for THC
SBC: ElSohly Laboratories, Incorporated Topic: N/ADESCRIPTION (provided by applicant): Delta-9-Tetrahydrocannabinol (THC), the active ingredient in the cannabis plant, has a wide range of pharmacological properties of therapeutic value. The drug has been approved by the Food and Drug Administration (FDA) (Marinol(r) soft gelatin capsules) for the treatment of nausea and vomiting associated with chemotherapy and for appetite stimulation in AIDS p ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health